These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 27666741

  • 1. Early ototoxic changes in patients with germ cell tumor after first cycle of cisplatin-based therapy.
    Noszek L, Budai B, Prekopp P, Széchenyi R, Szőnyi M, Talpai S, Nagyiványi K, Bíró K, Géczi L.
    Laryngoscope; 2017 Aug; 127(8):E277-E282. PubMed ID: 27666741
    [Abstract] [Full Text] [Related]

  • 2. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K.
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [Abstract] [Full Text] [Related]

  • 3. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D.
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [Abstract] [Full Text] [Related]

  • 4. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
    Biro K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I.
    Oncology; 2006 Dec; 70(3):177-84. PubMed ID: 16757924
    [Abstract] [Full Text] [Related]

  • 5. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
    Biró K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I.
    Magy Onkol; 2006 Dec; 50(4):329-35. PubMed ID: 17216007
    [Abstract] [Full Text] [Related]

  • 6. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
    Haugnes HS, Stenklev NC, Brydøy M, Dahl O, Wilsgaard T, Laukli E, Fosså SD.
    Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
    [Abstract] [Full Text] [Related]

  • 7. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
    Dille MF, McMillan GP, Reavis KM, Jacobs P, Fausti SA, Konrad-Martin D.
    J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
    [Abstract] [Full Text] [Related]

  • 8. GSTM1 null and GSTT1 null: predictors of cisplatin-caused acute ototoxicity measured by DPOAEs.
    Budai B, Prekopp P, Noszek L, Kovács ER, Szőnyi M, Erdélyi DJ, Bíró K, Géczi L.
    J Mol Med (Berl); 2020 Jul; 98(7):963-971. PubMed ID: 32435918
    [Abstract] [Full Text] [Related]

  • 9. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
    Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, Lipshultz SE, Dolan ME, Travis LB.
    J Clin Oncol; 2016 Aug 10; 34(23):2712-20. PubMed ID: 27354478
    [Abstract] [Full Text] [Related]

  • 10. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
    Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, Ellis M, Moody R, Stanton L, Galanopoulou A, Maishman T, Geldart T, Bayne M, Davies J, Lamb C, Popat S, Joffe JK, Nutting C, Chester J, Hartley A, Thomas G, Ottensmeier C, Huddart R, King E.
    Eur J Cancer; 2017 Dec 10; 87():75-83. PubMed ID: 29128692
    [Abstract] [Full Text] [Related]

  • 11. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
    Lisowska G, Namysłowski G, Hajduk A, Polok A, Tomaszewska R, Misiołek M.
    Otolaryngol Pol; 2006 Dec 10; 60(3):415-20. PubMed ID: 16989457
    [Abstract] [Full Text] [Related]

  • 12. Ototoxicity from cisplatin therapy in childhood cancer.
    Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL.
    J Pediatr Hematol Oncol; 2007 Jun 10; 29(6):355-60. PubMed ID: 17551394
    [Abstract] [Full Text] [Related]

  • 13. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
    Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG.
    HNO; 2007 Apr 10; 55(4):299-306. PubMed ID: 16437215
    [Abstract] [Full Text] [Related]

  • 14. Repeatability of high-frequency distortion-product otoacoustic emissions in normal-hearing adults.
    Dreisbach LE, Long KM, Lees SE.
    Ear Hear; 2006 Oct 10; 27(5):466-79. PubMed ID: 16957498
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.
    Konrad-Martin D, James KE, Gordon JS, Reavis KM, Phillips DS, Bratt GW, Fausti SA.
    J Am Acad Audiol; 2010 May 10; 21(5):301-14; quiz 357. PubMed ID: 20569665
    [Abstract] [Full Text] [Related]

  • 16. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
    Caballero M, Mackers P, Reig O, Buxo E, Navarrete P, Blanch JL, Grau JJ.
    Oncology; 2017 May 10; 93(2):75-82. PubMed ID: 28511189
    [Abstract] [Full Text] [Related]

  • 17. Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma.
    Bhagat SP, Bass JK, White ST, Qaddoumi I, Wilson MW, Wu J, Rodriguez-Galindo C.
    Int J Pediatr Otorhinolaryngol; 2010 Oct 10; 74(10):1156-63. PubMed ID: 20667604
    [Abstract] [Full Text] [Related]

  • 18. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
    Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC.
    JAMA Oncol; 2017 Nov 01; 3(11):1558-1562. PubMed ID: 28448657
    [Abstract] [Full Text] [Related]

  • 19. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
    Rolland V, Meyer F, Guitton MJ, Bussières R, Philippon D, Bairati I, Leclerc M, Côté M.
    J Otolaryngol Head Neck Surg; 2019 Jan 16; 48(1):4. PubMed ID: 30651130
    [Abstract] [Full Text] [Related]

  • 20. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.
    Stöhr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, Beck JD, German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology.
    Cancer Invest; 2005 Jan 16; 23(3):201-7. PubMed ID: 15945505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.